CMC Strategy Is Not a Static Document
There is a common misconception in early drug development that CMC strategy means writing a dossier. It does not. CMC strategy means making deliberate decisions, at every stage of development, about which data to generate, which manufacturing processes to lock, and how to position the product for the regulatory interactions that lie ahead.
The CMC strategy appropriate for an IND or Phase I IMPD filing is structurally different from the strategy needed to support a Phase II submission, and different again from what an NDA or MAA will require. A development team that treats its CMC work as a series of discrete filing exercises, rather than as a continuously evolving strategy, typically creates avoidable work and avoidable risk at each transition.
CMC Requirements at Each Development Stage
| Development Stage | Regulatory Filing | CMC Data Expectations | Key Decisions |
| Preclinical / IND-enabling | IND (US) / IMPD (EU) | Fit-for-purpose; sufficient to support safety of first dose. Process need not be final. | Solid form selection; initial specification setting; stability to cover trial duration |
| Phase I | IND amendment / IMPD update | Characterisation of development batches; preliminary stability. Process may still evolve. | Scale-up direction; control strategy development; method development roadmap |
| Phase II | IND amendment / clinical trial authorisation update | More complete characterisation; comparative dissolution if formulation changed; updated stability | Formulation and process lock or defined change control; bridging data if formulation changed |
| Phase III / NDA/MAA | NDA / MAA Module 3 | Full ICH Q6A specification; validated methods; 12 months real-time stability; process validation | Specification finalisation; scale-up and validation; regulatory starting material justification |
The Formulation Lock Decision
One of the most consequential CMC decisions in early development is when to lock the formulation. A formulation change between Phase I and Phase II is manageable with appropriate bridging data. A formulation change between Phase II and Phase III is significantly more costly and time-consuming, requiring bioequivalence or pharmacokinetic bridging data to justify the change to regulators.
The FDA’s guidance on comparability protocols and the EMA’s guidance on changes to approved products provide frameworks for managing post-approval changes, but the optimal strategy is to make the major formulation decisions as early as the data allows, so that the Phase II formulation is as close as possible to the one that will go into Phase III and registration.
Regulatory Starting Materials and Their Long-Term Impact
The designation of regulatory starting materials (RSMs) for the drug substance synthesis has long-term implications for the regulatory dossier and for commercial supply chain flexibility. Designating a starting material too early in the synthetic route creates a large regulatory footprint that is difficult to modify later. Designating it too late, at a complex intermediate, may not be accepted by regulators. Getting the RSM designation right at the IND stage, with a view to how the synthetic route will evolve through development and into commercial manufacture, is a decision that benefits from early input from an experienced CMC regulatory team.
Managing Formulation Changes with Bridging Data
It is unusual for the Phase I formulation to be identical to the commercial formulation. Scale-up changes, manufacturing process improvements, and changes driven by stability or bioavailability data all occur during development. Each change creates a potential regulatory question about whether the clinical data generated with the earlier formulation is still representative of the product being developed.
Bridging studies, whether dissolution comparisons, pharmacokinetic crossover studies, or formal bioequivalence studies, provide the evidence base for justifying formulation changes to health authorities. Planning for these studies as part of the CMC strategy, rather than retrospectively, avoids last-minute surprises at the Phase II or III transition.
How Ardena Builds CMC Strategy into Development Programmes
Ardena’s CMC regulatory advisors work alongside the formulation and analytical teams throughout development programmes, not just at filing milestones. This means that the CMC strategy is reviewed and updated as the science evolves, and that decisions with long-term regulatory implications, such as solid form selection, RSM designation, and specification setting, are made with full visibility of their downstream consequences.
For programmes approaching the Phase I to Phase II transition, Ardena can conduct a CMC gap analysis against the requirements for the next regulatory filing and identify the studies needed to close those gaps efficiently.
